Urgent need to address infectious diseases due to immunosuppressive therapies

Affiliations

¹ Clinical Associate Professor, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701, USA.
² Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA.

Editorial

Daniel B Chastain et al. Ther Adv Infect Dis. 2023.

. 2023 Apr 29:10:20499361231168512.

doi: 10.1177/20499361231168512. eCollection 2023 Jan-Dec.

¹ Clinical Associate Professor, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701, USA.
² Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA.

No abstract available

Keywords: biological therapy; glucocorticoids; immunosuppression therapy; immunotherapy; molecular targeted therapy; opportunistic infections.

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

1. Parkin J, Cohen B.An overview of the immune system. Lancet 2001; 357: 1777–1789. - PubMed
1. Wallace BI, Kenney B, Malani PN, et al. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018–2019. JAMA Netw Open 2021; 4: e214920. - PMC - PubMed
1. Fauci AS, Dale DC, Balow JE.Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304–315. - PubMed
1. McLean-Tooke A, Aldridge C, Waugh S, et al. Methotrexate, rheumatoid arthritis and infection risk – what is the evidence? Rheumatology 2009; 48: 867–871. - PubMed
1. Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 2018; 24(Suppl. 2): S53–S70. - PubMed